secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2023-07-21T23:59:59+00:00
Accession:  0001628280-23-025293
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 2.04, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo enters forbearance on venture debt default and signs non-binding LOI to sell 800 series for $150K upfront
--------------------------------------------------------------------------------

- Forbearance until Aug 15, 2023; company must keep cash >= $3M plus 100% of future equity proceeds.
- Preliminary cash and equivalents ~$4.5M as of July 20, 2023 (unaudited).
- Non-binding LOI to sell AVTX-801, -802, -803 for $150K upfront, up to $45M in FDA approval milestones.
- Holders asserted default due to material adverse change; forbearance halts enforcement until mid-August.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023025293/0001628280-23-025293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023025293/avtx-20230720.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-025293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer